-
HELIOS-B Phase 3 Topline Results
Alnylam announces positive topline results from the Phase 3 clinical trial of vutrisiran
Learn More ›
-
Corporate Responsibility at Alnylam
We’ve published our fourth annual Corporate Responsibility Report
Learn More ›
-
Alnylam Publishes 2023 Annual Report
CEO Yvonne Greenstreet highlights another year of continued RNAi innovation
Learn More ›
-
Alnylam Named #1 Largest Employer in Massachusetts 3 Years in a Row
This is our 9th consecutive year on
The Boston Globe Top Places to Work list
Learn More ›
Alnylam Named #1 Largest Employer in Massachusetts 3 Years in a Row
This is our 9th consecutive year on The Boston Globe Top Places to Work list
-
Alnylam Named One of America’s Most Responsible Companies
Our efforts in ESG have earned us recognition from Newsweek two years in a row
Learn More ›
-
Alnylam & Roche Announce Zilebesiran Partnership
Together will co-develop and co-commercialize investigational anti-hypertensive RNAi therapeutic
Learn More ›